Aiming to make the impossible, possible
Our
Mission
To transform the lives of people with severe diseases by developing and commercializing potentially curative treatments.
Learn more
Intellia Reports World's First Phase 3 In Vivo Gene Editing Data
Positive topline results from Phase 3 clinical trial in hereditary angioedema and submission of rolling biologics license application (BLA) to FDA for lonvoguran ziclumeran announced
PATIENT STORIES
Kim
Living with Hereditary Angioedema
PATIENT STORIES
Shanna
Living with Hereditary Angioedema Type 1
PATIENT STORIES
Nancy
Living with ATTR Amyloidosis with Polyneuropathy
PATIENT STORIES
Milton
Living with ATTR Amyloidosis with Cardiomyopathy
Our
